| |
Dendreon's Provenge gets FDA review date
Fri 10:54 am ET (AP)
Biotechnology company Dendreon Corp. said Friday the Food and Drug Administration will make a regulatory decision on the potential prostate cancer vaccine Provenge by May 1.
|
|
Top-Ranked Analysts
|
Provided by StarMine
|
| | |
Locate Industry by Company
|
| Market Capitalization: | 225B | | Price
/ Earnings: | 152.2 | | Price
/ Book: | 7.6 | | Net
Profit Margin (mrq): | 8.5% | | Price
To Free Cash Flow (mrq): | 52.1 | | Return
on Equity: | 6.0% | | Total
Debt / Equity: | 0.0 | | Dividend
Yield: | 2.5% |
|